Applicant: Alan D. Snow et al. Serial No.: 10/077,596 Filed: February 15, 2002

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-27. (Canceled)

28. (Currently amended) A pharmaceutical composition consisting of a therapeutically effective amount of a proanthocyanidin, selected from a group of proanthocyanidins characterized by Formula I or Formula II, and proanthocyanidins characterized by oligomeric combinations of Formula I and Formula II, and pharmaceutically acceptable salts of the foregoing proanthocyanidins:

where:

n is an integer of 2 to 20;

R₁ and R₂ are independently selected from hydrogen and hydroxy:

Ra is selected from the group consisting of hydrogen, optionally substituted O-glycosyl,

-C(O) (optionally substituted aryl), and BC(O) (optionally substituted heteroaryl);

R4 is selected from the group consisting of hydrogen, catechin, epicatechin, epiafzelechin, and gallates of catechin and epicatechin:

the lines at the 2-, 3- and 4-position denote optional R and S configurations;

the lines at the 4- and 8-positions in Formula I and at the 4- and 6- positions in Formula II denote possible oligomer bonds between individual units, and

the substitutions at R₁, R₂, R₃, and R₄, and the configurations at the 2 · . 3 · and 4 positions, and the oligomer bond configurations of 4 8 and 4 6 are independently selected for each individual unit and a pharmaceutically acceptable carrier, diluent, or excipient,

Attorney's Docket No.: 017170-0010-999 CAM No.: 712576-999005

Applicant: Alan D. Snow et al. Serial No.: 10/077,596 Filed: February 15, 2002

epicatechin-4 β -8-epicatechin, wherein the therapeutic amount of the proanthoeyanidin epicatechin-4 β -8-epicatechin is selected for efficacy in treating amyloid, α -synuclein or NAC fibrillogenesis in a mammalian subject.

- 29. (Currently amended) The composition of claim 28, wherein the therapeutically effective amount of the proanthoeyanidin epicatechin-4β→8-epicatechin, comprises a dosage in the range of about 10 to 1,000 mg/kg of body weight of the subject.
- 30. (Currently amended) The composition of claim 29, wherein the therapeutically effective amount of the proanthoeyanidin epicatechin-4B→8-epicatechin, comprises a dosage in the range of about 10 to 100 mg/kg of body weight of the subject.

31-56. (Canceled)